Certificate of Mailing 37 C.F.R. §1.8(a) ertify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Name of Person Signing Certificate: Renee Con Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Cristina Blanco

§ §

Fernandez, et al

8298

Group Art Unit: 1621

Appln. No.:

Conf. No.:

10/799,909

Examiner:

Peter G. O'Sullivan

Filing Date:

March 12, 2004

§ Attorney Docket No.: 9256-23US

(003/PCT/05-V)

Title: PROCESS FOR THE SEPARATION OF R(-)- AND S(+)-5-[2-[[2-(2-

ETHOXYPHENOXY)ETHYL|AMINO|PROPYL]-2-

METHOXYBENZENESULFONAMIDE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

Enclosed are copies of each of the documents listed on the attached Information Disclosure Citation Form(s) PTO/SB/08A, which may be material to the patentability of this application and/or for which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

The enclosed references were cited in an International Search Reported dated February 5, 2004 (copy enclosed) from the Spanish Patent and Trademark Office concerning counterpart International Application No. PCT/ES 03/00357.

The filing of this Information Disclosure Statement shall not be construed as an admission that any of the listed documents constitutes prior art, nor as an admission against interest in any manner.

No fee is believed to be due in connection with the filing of this Information Disclosure Statement since it is being filed before the mailing date of the first Office Action on the ments. However, the Commissioner is hereby authorized to charge any deficiencies or credit any

overpayments to Deposit Account No. 50-1017.

It is respectfully requested that this Information Disclosure Statement and the documents listed on the attached Form PTO/SB/08A be considered and acknowledged by the Examiner in connection with the above-identified patent application, be made of record therein, and that the listed document(s) be cited in the issued patent.

Respectfully submitted,

Cristina Blanco Fernandez, et al

William W. Schwarze

Attorney/Agent for Applicant(s)

Registration No. 25,918 Direct Dial: 215-965-1270

E-Mail: wschwarze@akingump.com

Akin Gump Strauss Hauer & Feld LLP

One Commerce Square

2005 Market Street, Suite 2200

Philadelphia, PA 19103

Telephone No.: 215-965-1200

Fax No.: 215-965-1210

WWS:rc Enclosures

JAN 1 87	ريخ كال					
Form PTO/S#/Ø8A				Complete if Known		
TE TRADE	MA			Application Number	10/799,909	_
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	March 12, 2004	
			ICANT.	First Named Inventor	Cristina Blanco Fernandez, et al	
				Group Art Unit	1621	
			ecessary)	Examiner Name	Peter G. O'Sullivan	
Sheet	Τ1	of	1	Attorney Docket Number	9256-23US (003/PCT/05-V)	

		U.S	S. PATENT DOCUMENTS		
Exr Initials	U.S. Patent Document Number Kind Code (if known)		Name of First Inventor of Cited Document	Date of Publication of Cited Document MM-YYYY	
	5,447,958		Niigata et al.	09-1995	

		-	FOREIGN PATE	NT DOCUMENTS		
		Foreign Patent Docum		Name of Applicant of Cited Document	Date of	T ₁
Exr Initials	Country Code	Number	Kind Code (if known)		Publication of Cited Document MM-YYYY	
	ES	2 000 382		Yamanouchi Pharmaceutical Co., Ltd.	02-1988	
	ES	2 029 838		Yamanouchi Pharmaceutical Co., Ltd.	10-1992	
	WO	03/037856	A1	Roche Vitamins AG	05-2003	
			,			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Exr Initials	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.					
						

Examiner	Date	
Signature	Considered	